Abstract
The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established.
Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.
Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-12 |
| Journal | Journal of Translational Science |
| Volume | 7 |
| DOIs | |
| State | Published - May 28 2020 |
Keywords
- COVID-19
- SARS-CoV-2
- coronavirus
- antiviral
- inflammation
- coagulation
ASJC Scopus subject areas
- Biochemistry, medical